Enterococcus News and Research RSS Feed - Enterococcus News and Research

Hussey Copper launches new line of home improvement products that fight deadly bacteria

Hussey Copper, a leader in copper manufacturing, with support from Lynn Tilton and Patriarch Partners, today launches a new line of home improvement products that fight deadly bacteria known to lurk on surfaces. [More]
AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

AmpliPhi BioSciences Corporation, the leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, announces it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile, a serious gastrointestinal infection for which new treatments are urgently required. [More]

Use of gloves, gowns by health care workers for ICU patient contact does not reduce MRSA infection

The wearing of gloves and gowns by health care workers for all intensive care unit (ICU) patient contact did not reduce the rate of acquisition of a combination of the bacteria methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), although there was a lower risk of MRSA acquisition alone, according to a study published online by JAMA. [More]

Universal Gown And Glove Use By Health-Care Workers In ICU Reduces MRSA 40 Percent

​Healthcare workers' use of disposable gowns and gloves upon entering all patient rooms on an intensive care unit (ICU), versus only in rooms on standard isolation protocol, helped reduce patient acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by approximately 40 percent, according to new research co-led by the University of Maryland School of Medicine and the Yale New Haven Health System Center for Healthcare Solutions. [More]
Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Investigators working to stem the spread of antibiotic-resistant bacteria have taken a major step in their efforts to develop new treatments. [More]
Kansas researchers defeat persistent bacteria known for causing infections in hospitals

Kansas researchers defeat persistent bacteria known for causing infections in hospitals

Kansas State University researchers are defeating persistent bacteria known for causing infections in hospitals. [More]
Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis. [More]
University of Granada researchers patent new treatment for acne

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects. [More]
Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. [More]

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila. [More]

Study shows copper objects in ICUs reduce healthcare-acquired infections by 50%

Placement of copper objects in intensive care unit (ICU) hospital rooms reduced the number of healthcare-acquired infections (HAIs) in patients by more than half, according to a new study published in the May issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, in a special topic issue focused on the role of the environment in infection prevention. [More]
Left-sided brain injury increases infection risk

Left-sided brain injury increases infection risk

Patients with a left-sided brain injury are more likely to develop hospital-acquired infections than those with right-sided injury, show study findings. [More]

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). [More]

Reintroducing normal microbial diversity can eliminate VRE from intestinal tracts

Too much antibiotic can decimate the normal intestinal microbiota, which may never recover its former diversity. That, in turn, renders the GI tract vulnerable to being colonized by pathogens. Now researchers from Memorial Sloan-Kettering Cancer Center, New York, NY, and Centro Superior de Investigaci-n en Salud P-blica, Valencia, Spain, show that reintroducing normal microbial diversity largely eliminated vancomycin-resistant enterococci (VRE) from the intestinal tracts of mice.. [More]

Chlorhexidine bathing protects vulnerable hospital patients

Bathing hospital patients with chlorhexidine-impregnated washcloths reduces the risk for them acquiring multidrug-resistant organisms and developing bloodsteam infections, show study findings. [More]
Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers. [More]
Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

While working out the structure of a cell-killing protein produced by some strains of the bacterium Enterococcus faecalis, researchers stumbled on a bit of unusual biochemistry. They found that a single enzyme helps form distinctly different, three-dimensional ring structures in the protein, one of which had never been observed before. [More]

Bacteriophages may play an important role in competition among bacterial strains

Unique viruses called bacteriophages may play an important role in competition among bacterial strains, influencing the overall ecosystem of the human intestine, scientists at The University of Texas at Arlington and UT Southwestern Medical Center say. [More]

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP). [More]

Metalloacid surfaces may be answer to hospital-acquired infections

Coating surfaces in metalloacids may help control the spread of hospital-acquired infections, suggest study findings. [More]